Michael Austwick - 01 Feb 2024 Form 4 Insider Report for Verona Pharma plc (VRNA)

Reporting relationship: Director
Issuer ticker: VRNA
Reported as of: 01 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Feb 2024, 06:07:24 UTC
Next SEC filing: 29 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Claire Poll, Attorney-in-Fact for Michael Austwick

Key filing fact

Michael Austwick filed Form 4 for Verona Pharma plc (VRNA) on 02 Feb 2024.

Key facts

This page summarizes Michael Austwick's Form 4 filing for Verona Pharma plc (VRNA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Feb 2024, 06:07.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRNA transaction Derivative

Share Options (Right to Buy)

Award

Transaction value: $0
Shares: +144,000
Change %
Price: $0.000000
Shares after: 144,000
Date: 01 Feb 2024
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 144,000
Exercise price: $2.29
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Footnote F2

The option vests and becomes exercisable as to one-third of the underlying options on February 1, 2025 and the remainder in eight equal quarterly installments thereafter.